



**EXHIBIT B: PENDING CLAIMS**

**APPLICATION NO. 09/547,220**

**Attorney Docket No. 10165-006-999**

**(as amended under 37 C.F.R. §1.116 on December 18, 2002)**

---

**WHAT IS CLAIMED IS:**

28. A method for treating cerebral ischemia in a mammal comprising peripherally administering to said mammal a non-toxic amount of erythropoietin effective to exert a neuroprotective effect.

29. The method of Claim 28 wherein said administering is carried out in a vascular fashion.

30. The method of Claim 29 wherein said vascular administration is intravenous.

31. The method of Claim 28, 29, or 30 wherein said erythropoietin is administered for the treatment of stroke.

32. The method of Claim 28, 29 or 30 wherein said erythropoietin is administered at a dosage of 50,000 to 100,000 Units per administration or per day.

33. The method of Claim 28, 29, or 30 wherein said erythropoietin is native erythropoietin, recombinant human erythropoietin or animal erythropoietin or a derivative thereof.

34. A method for treating cerebral ischemia in a human subject comprising peripherally administering to said human subject a non-toxic amount of erythropoietin effective to exert a neuroprotective effect.

35. The method of Claim 34 wherein said administering is carried out in a vascular fashion.

36. The method of Claim 34 wherein said vascular administration is intravenous.

37. The method of Claim 34, 35, or 36 wherein said erythropoietin is administered for the treatment of stroke.

38. The method of Claim 34, 35, or 36 wherein said erythropoietin is administered at a dosage of 50,000 to 100,000 Units per administration or per day.

39. The method of Claim 34, 35, or 36 wherein said erythropoietin is native erythropoietin, recombinant human erythropoietin or animal erythropoietin or a derivative thereof.

40. A method for treating cerebral ischemia in a mammal comprising peripherally administering to said mammal an amount of erythropoietin effective to exert a neuroprotective effect without a toxic increase in hemoglobin concentration or hematocrit.

41. The method of Claim 40 wherein said administering is carried out in a vascular fashion.

42. The method of Claim 40 wherein said vascular administration is intravenous.

43. The method of Claim 40, 41, or 42 wherein said erythropoietin is administered for the treatment of stroke.

44. The method of Claim 40, 41, or 42 wherein said erythropoietin is administered at a dosage of 50,000 to 100,000 Units per administration or per day.

45. The method of Claim 40, 41, or 42 wherein said erythropoietin is native erythropoietin, recombinant human erythropoietin or animal erythropoietin or a derivative thereof.

46. A method for treating cerebral ischemia in a human subject comprising peripherally administering to said human subject an amount of erythropoietin effective to exert a neuroprotective effect without a toxic increase in hemoglobin concentration or hematocrit.

47. The method of Claim 46 wherein said administering is carried out in a vascular fashion.

48. The method of Claim 47 wherein said vascular administration is intravenous.

49. The method of Claim 46, 47, or 48 wherein said erythropoietin is administered for the treatment of stroke.

50. The method of Claim 46, 47, or 48 wherein said erythropoietin is administered at a dosage of 50,000 to 100,000 Units per administration or per day.

51. The method of Claim 46, 47, or 48 wherein said erythropoietin is native erythropoietin, recombinant human erythropoietin or animal erythropoietin or a derivative thereof.

52. A method for treating cerebral ischemia in a mammal comprising peripherally administering to said mammal an amount of erythropoietin effective to exert a neuroprotective effect without an increase in hematocrit in said mammal.

53. The method of Claim 52 wherein said administering is carried out in a vascular fashion.

54. The method of Claim 53 wherein said vascular administration is intravenous.
55. The method of Claim 52, 53, or 54 wherein said erythropoietin is administered for the treatment of stroke.
56. The method of Claim 52, 53, or 54 wherein said erythropoietin is administered at a dosage of 50,000 to 100,000 Units per administration or per day.
57. The method of Claim 52, 53, or 54 wherein said erythropoietin is native erythropoietin, recombinant human erythropoietin or animal erythropoietin or a derivative thereof.
58. A method for treating cerebral ischemia in a human subject comprising peripherally administering to said human subject an amount of erythropoietin effective to exert a neuroprotective effect without an increase in hematocrit in said human subject.
59. The method of Claim 58 wherein said administering is carried out in a vascular fashion.
60. The method of Claim 58 wherein said vascular administration is intravenous.
61. The method of Claim 58, 59, or 60 wherein said erythropoietin is administered for the treatment of stroke.
62. The method of Claim 58, 59, or 60 wherein said erythropoietin is administered at a dosage of 50,000 to 100,000 Units per administration or per day.
63. The method of Claim 58, 59, or 60 wherein said erythropoietin is native erythropoietin, recombinant human erythropoietin or animal erythropoietin or a derivative thereof.